1. Introduction {#s0005}
===============

Major depressive disorder (MDD) and bipolar disorder (BD) are two major types of mood disorder. Although mania or hypomania is a defining feature of BD patients, the presence of subthreshold manic symptoms can be observed in both disorders during a depressive episode ([@bb0070]). This leads to difficulty in distinguishing BD from MDD patients as they have the same diagnostic criteria for a depressive episode ([@bb0245]). Actually, misdiagnosing BD as MDD has many potentially deleterious consequences because treatment with antidepressants in the absence of a mood stabilizer carries the risk of precipitating mania and may increase rates of cycling between mood states ([@bb0010]). In fact, whether MDD and BD have different neural mechanisms or share some in common remains ambiguous ([@bb0070], [@bb0250]). Neuroimaging studies have identified a number of differences between patients with depressive disorders and healthy controls in brain structure and function. Until now, it is still unclear to what extent specific or common morphological alterations occur in MDD and BD given the paucity of direct comparisons.

Based on brain structural images, brain morphologic characteristics have been studied in various brain diseases ([@bb0075], [@bb0255]). Using the voxel-based morphometry (VBM) method, some studies detected altered brain GM volume or density in patients with MDD or BD ([@bb0260]) and found between-group difference in GM volume primarily in the prefrontal cortex (PFC), anterior cingulate gyrus (ACG), amygdala, and hippocampus ([@bb0260], [@bb0210]). Actually, the VBM method is susceptible to several potential confounds, including the accuracy of the brain segmentation, degree of smoothing, strategies used in registration, and the choice of a normalization template ([@bb0040]). Especially, VBM analysis is a method of measuring MRI signal alteration in brain tissue rather than a directly technique to detect brain structural alteration about the volume size of a region, CT and cortical surface area ([@bb0040]). CT analysis is similar to VBM, albeit the analysis is performed at the nodes of a 3D polygonal mesh rather than on a 3D voxel grid. And the CT analysis has the advantage of providing a direct quantitative index (in unit of mm), rather than qualitative index, of cortical morphology. Therefore, the measurement of CT alteration has been suggested as a way to obtain a complementary indication of alterations in brain GM morphology ([@bb0100]).

For depressive disorders, previous studies focused primarily on CT alteration in just one of the depressive disorders, comparing the patients with healthy controls ([@bb0260], [@bb0265]), but ignoring the abnormal CT between the two disorders. Several studies of BD patients reported subtle but widespread CT abnormalities and showed decreased CT in the left anterior cingulate/paracingulate, left superior temporal gyrus and prefrontal regions ([@bb0275], [@bb0270], [@bb0165]). And several studies of MDD patients reported reduced CT in the medial orbitofrontal gyrus and pars opercularis ([@bb0280], [@bb0285]), and a study reported increased CT in similar regions ([@bb0290]). By now, very few studies have directly compared the difference in brain CT between MDD and BD patients ([@bb0215], [@bb0140]), and those that did obtained partially inconsistent results. For example, [@bb0215] investigated the difference in CT between 18 BD patients and 56 MDD patients and reported thinner CT in the right caudal middle frontal cortex, left inferior parietal cortex, and right precuneus in a mixed group of BD-I and BD-II patients. However, [@bb0140] failed to find any brain regions with differences in CT between MDD and BD patients. Notably, in these two studies, the analyses were performed on patients who were taking medications, which may have influenced the results.

The CT analysis may be affected by several factors, such as sample sizes, medication status ([@bb0220], [@bb0130]), or heterogeneity in the patient samples. Most studies published to date have included patients who were taking medications. Although the effects of medication on brain morphology are not yet fully understood, several studies have indicated that the use of psychotropic medications, such as lithium, may cause an increase in GM volume in the cortical and subcortical regions ([@bb0130], [@bb0050]). [@bb0220] and [@bb0025] reported that the alteration of brain structure may be resulted from the use of selective serotonin reuptake inhibitors (SSRI). The heterogeneity of patient samples included the age of the participants, their mood states at the time of scanning, and mixing the types of BD patients. As for BD patient, BD-II might have a genetic etiology distinguishable from BD-I ([@bb0200]). BD-II is especially difficult to diagnose accurately because of the difficulty in differentiating this disorder from recurrent MDD (recurrent depressive episodes) in depressed patients ([@bb0245]). Unfortunately, no study has yet directly compared differences in CT between MDD patients and BD-II, although a few studies compared brain CT in combined samples of BD-I, BD-II and BD not otherwise specified (BD-NOS) patients with MDD patients ([@bb0070], [@bb0215]).

In this study, our goal was to detect alteration of CT in the unmedicated adult MDD and BD-II patients who were in a depressive episode, and compare to the healthy controls to assess morphometric differences and similarities that may reflect common and/or distinct brain regions in affective disorders. Considering the similarities and differences in the clinical symptoms and brain alterations revealed in previous studies ([@bb0070], [@bb0215]), we hypothesized that depressive episode unmedicated adult MDD and BD-II patients would not only have CT abnormalities that they shared in common but also abnormalities in CT that are specific to each disease. Considering the similarities and differences in clinical symptoms and brain alterations revealed in previous studies ([@bb0070], [@bb0215]), we hypothesized that the depressive unmedicated adult MDD and BD-II patients would not only have CT abnormalities that they shared in common but also abnormalities in CT that are specific to each disorder. And these abnormal regions would likely be the key brain structures involving in depression symptoms, such as the limbic and prefrontal regions. In addition, as BD is considered to have more complexity and severity than MDD, we supposed that the BD patients had more widespread CT abnormalities than the MDD patients.

2. Methods and Materials {#s0010}
========================

2.1. Subjects {#s0015}
-------------

A total of 68 currently unmedicated depressed patients and 30 healthy controls were recruited from the Psychiatry Department of the First Affiliated Hospital of Jinan University (FAHJU), Guangzhou, China, during July 2013--August 2015. All the subjects were determined to have no abnormalities on conventional MRI by two experienced radiologists (Y.W. and Y.S.) and were right-handed according to the Edinburgh Handedness Inventory ([@bb0295]). The three groups of subjects, MDD (17M/19F, aged 18--43 years old), BD (15M/17F, aged 18--50 years old), healthy controls (17M/13F, aged 19--44 years old), were matched on age and gender. The study was approved by the Institute Review Board of the First Affiliated Hospital of Jinan University, China. Each subject signed a written informed consent form after a full written and verbal explanation of the study. [Table 1](#t0005){ref-type="table"} lists the detailed demographics for all the subjects in this study.Table 1Demographics and clinical data.[a](#tf0005){ref-type="table-fn"}Demographic characteristics of the adult unmedicated patients with major depressive disorder (MDD) and bipolar depression (BD), as well as the healthy controls (HC) in this study. Abbreviations: HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale; N/A, not applicable.Table 1CharacteristicsMDDBDHCStatistic[b](#tf0010){ref-type="table-fn"}*p*-ValuePost-hoc[e](#tf0025){ref-type="table-fn"}General demographics Age (years old)29.08 ± 7.1628.78 ± 8327.83 ± 6.38*F* = 0.250.78 Gender (M/F)17/1915/1717/13*X*^2^ = 0.770.68 Handedness (right/left)36/032/030/0 Education (years)[c](#tf0015){ref-type="table-fn"}13.56 ± 2.7614.72 ± 2.5015.56 ± 2.33*F* = 5.180.007[⁎⁎](#tf0030){ref-type="table-fn"}MDD vs. BD; *p* = 0.064\
MDD vs. HC; *p* = 0.002\
BD vs. HC; *p* = 0.194 Onset age (years old)24.92 ± 7.3224.28 ± 9.85N/A*t* = 0.300.76 Total duration (months)42.06 ± 61.6033.56 ± 50.14N/A*t* = 0.620.54Disorder characteristics No. of episodes[d](#tf0020){ref-type="table-fn"}1.83 ± 1.252.37 ± 1.23N/A*t* = − 1.790.07 HDRS scores26.67 ± 4.7326.50 ± 4.77N/A*t* = 0.140.88 YMRS scores2.75 ± 2.511.84 ± 1.80N/A*t* = 1.690.007[⁎⁎](#tf0030){ref-type="table-fn"}[^2][^3][^4][^5][^6][^7]

The MDD and BD patients were diagnosed according to the DSM-IV criteria and the Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P) ([@bb0300]). All patients fulfilled the criteria for either MDD or BD. Diagnosis of patients was determined by two experienced clinical psychiatrists (Y.J. and S.Z., with 20 and 5 years of experience in clinical psychiatry, respectively). Current depressive symptoms were assessed by using the 24-item Hamilton Depression Rating Scale (HDRS) ([@bb0305]) and current manic symptoms were assessed by the Young Mania Rating Scale (YMRS) ([@bb0310]) during the 7-day period before the imaging session. All patients with BD or MDD were diagnosed with depression (a YMRS score \< 7 and a total HDRS score \> 21). The exclusion criteria for the patients were other Axis-I psychiatric disorders, a history of organic brain disorder or neurological disorders, mental retardation, cardiovascular diseases, pregnancy, or any physical illness. None of the subjects had lifetime substance use disorders, including alcohol abuse, marijuana use, and cocaine abuse. None of the patients had ever received electroconvulsive therapy prior to participating in this study. The exclusion criteria for the healthy controls were same to the patients, in addition to any history of psychiatric illness in first-degree relatives and current or past significant medical or neurological illness. At the time of the scanning, 37 patients (18 BD and 19 MDD) were medication-naïve; they had never been diagnosed or did not want to take medication. While for the others, the recruited patients generally visited their physicians (psychiatrist/general practitioner) because of depressive relapse after quitting medication. Among them, 14 BD patients had been treated with antidepressants (duloxetine or paroxetine), and/or mood stabilizers (lithium, sodium valproate), and/or atypical antipsychotic medications (olanzapine or risperidone), and 17 MDD patients had been treated with antidepressants (duloxetine or paroxetine). For all of the patients, they had been off medication for at least 6 months prior to the scan.

2.2. Image Acquisition {#s0020}
----------------------

All the MRI data were acquired on a 3 T GE MR750 scanner with an eight-channel phased-array head coil in the Medical Imaging Department, the First Affiliated Hospital of Jinan University, Guangzhou. For each subject, we obtained high resolution brain structural images by using a T1-weighted 3D Ax FSPGR BRAVO sequence. The sequence parameters were as follows: repetition time (TR) = 8.2 ms, echo time (TE) = 3.2 ms, flip angle (FA) = 12°, data matrix = 256 × 256, field of view (FOV) = 256 mm × 256 mm, slice thickness = 1.0 mm, and 136 axial slices covering the whole brain. In addition, two routine scans using axial T1-weighted fluid attenuation inversion recovery (FLAIR) and fast spin-echo T2-weighted MR sequences were also applied to obtain brain images to confirm the absence of any brain structural abnormalities.

2.3. Image Processing {#s0025}
---------------------

We first visually inspected all the T1-weighted brain structural data to exclude poor quality images. Then we inputted them into a FreeSurfer software package (version 5.3.0, <http://surfer.nmr.mgh.harvard.edu>), a widely documented and automated program for reconstructing brain cortical surfaces and calculating CT ([@bb0125]). In brief, the reconstruction processes involved the following steps: 1) correcting for small head motions and signal intensity non-uniformity in the structural images, 2) removing the non-brain tissue, 3) segmenting the brain into the GM and WM, 4) labeling the subcortical structures and computing statistics on the segmented subcortical structures, 5) performing a surface tessellation to generate triangular cortical meshes in the GM/WM boundary and GM/CSF (cerebrospinal fluid) boundary, 6) smoothing the fold surface and inflating it, and 7) finding topological defects and removing or fixing them automatically or manually ([@bb0065], [@bb0115], [@bb0120], [@bb0110]). After these preliminary reconstruction processes, we measured two shortest distances, from the GM/WM boundary to the GM/CSF boundary and from the GM/CSF boundary to the GM/WM boundary at each vertex and averaged these two values as the CT at the given vertex. For each subject, we morphed and used a spherical transform to register the reconstructed brain to an average spherical surface and mapped the thickness measurement at each vertex on a common spherical coordinate system. In the calculations, we adopted a smoothing Gaussian kernel with a full-width half-maximum (FWHM) of 10 mm.

2.4. Statistical Analysis {#s0030}
-------------------------

### 2.4.1. Demographics and Questionnaires {#s0035}

One-way analyses of variance (ANOVA) with Bonferroni post hoc tests were performed to detect group differences in age and education level. A *χ*^2^-test was used to assess the gender composition across the three groups. An independent two-sample *t*-test was used to determine differences in the onset age, illness duration, number of episodes, HDRS scores, and YMRS scores between the MDD and BD patients. All these statistical analyses were performed using SPSS 17.0 (<http://www.spss.com>).

### 2.4.2. Vertex-based Analysis {#s0040}

A vertex-based analysis was conducted using the FreeSurfer Qdec application by fitting a general linear model (GLM) at each vertex to compare the CT between the different groups. Specifically, the measurement of CT (*y*~*ij*~) and the main effect of group (*G*~*i*~) were estimated by regression using a GLM at each vertex *i* for subject *j*, with the gender and age as covariates:$$y_{\mathit{ij}} = \beta_{1}\ G_{j} + \beta_{2}\ \text{Gender}_{j} + \beta_{3}\ {Age}_{j} + \varepsilon_{\mathit{ij}},$$where *β*~1~, *β*~2~ and *β*~3~ correspond to coefficients of various factors, and *ε* to the residual error. Between-group differences in the CT were estimated from the fixed-effect coefficient *β*~1~ normalized by the corresponding standard error. Corrections for multiple comparisons across the whole brain were performed using a Monte Carlo permutation cluster analysis (5000 iterations) with a cluster-based threshold of *p* \< 0.05. Once a significant between-group difference was observed for a parameter, we estimated its effect size (Cohen *d*) and statistical power according to the Cohen\'s definition (1992). The clusters with significant between-group difference in CT were preserved for subsequent analysis.

### 2.4.3. Cluster-based Analysis {#s0045}

For each of the clusters showing a significant between-group difference, we mapped the cluster to each individual brain, extracted the thickness at each vertex, and estimated the mean thickness in this cluster for each subject. Then, we calculated the average CT for each group. Subsequently, we conducted between-group comparisons for each cluster by taking age and gender as covariates.

#### 2.4.3.1. Rank Analysis {#s0050}

A non-parametric analysis ([@bb0255]) was used to assess the rank of the average CT in each cluster among the three groups. There were six possible rankings of the CT, which are as follows: (i) *CT*~HC~ \> *CT*~MDD~ \> *CT*~BD~, (ii) *CT*~HC~ \> *CT*~BD~ \> *CT*~MDD~, (iii) *CT*~MDD~ \> *CT*~HC~ \> *CT*~BD~, (iv) *CT*~MDD~ \> *CT*~BD~ \> *CT*~HC~, (v) *CT*~BD~ \> *CT*~MDD~ \> *CT*~HC~, and (vi) *CT*~BD~ \> *CT*~HC~ \> *CT*~MDD~, where *CT*~MDD~, *CT*~BD~, and *CT*~HC~ represents the values of the average CT at a given cluster for the MDD patients, BD patients, and healthy controls, respectively. In the end, we determined the rank order of the average CT in each cluster.

#### 2.4.3.2. Relative Alterations {#s0055}

For each cluster showing a significant between-group difference in the CT, we estimated the relative alteration (*RA*) in the CT by using the following equations:$$\left. \mathit{RA}_{{BD} - {MDD}} = \left( {\mathit{CT}_{BD} - \mathit{CT}_{MDD}} \right)/\mathit{CT}_{MDD}, \right.$$$$\left. \mathit{RA}_{{MDD} - {HC}} = \left( {\mathit{CT}_{MDD} - \mathit{CT}_{HC}} \right)/\mathit{CT}_{HC}, \right.$$$$\left. \mathit{RA}_{{BD} - {HC}} = \left( {\mathit{CT}_{BD} - \mathit{CT}_{HC}} \right)/\mathit{CT}_{HC}, \right.$$where *RA*~MDD-HC~ (*RA*~BD-HC~) represents the alteration of the CT in the MDD (BD) patients relative to the controls, and *RA*~BD-MDD~ represents the alteration of the CT in the BD patients relative to the MDD patients, for a given cluster.

#### 2.4.3.3. Relationship Between CT and Clinical Variables {#s0060}

We also calculated the partial Pearson\'s correlation coefficients between the average CT in each cluster and each of the clinical variables (onset age, illness duration, number of depressive episodes, and HDRS scores) for the MDD and BD patients separately. In the calculations, we regressed out the confounding factors of age and gender ([@bb0315], [@bb0320]). After calculated the partial Pearson\'s correlation, we applied a false discovery rate (FDR) correction.

3. Results {#s0065}
==========

3.1. Demographics and Questionnaires {#s0070}
------------------------------------

No significant between-group differences were found for age, gender, or handedness. Additionally, no significant differences between the MDD and BD groups were found in depression severity (HDRS score), illness duration, illness onset age, or number of episodes. Also, the MDD patients showed significantly higher YMRS scores than the BD patients (*p* = 0.007).

3.2. Vertex-based Analysis {#s0075}
--------------------------

[Fig. 1](#f0005){ref-type="fig"} shows the clusters with a significant between-group difference in the CT. For each of three between-group comparisons, MDD vs. BD, MDD vs. HC, and BD vs. HC, in the CT, the detailed information is described as follows.MDD vs. BD: There is only one cluster that was thinner in patients with BD compared to MDD (referred to as C1), which is located in the left rostral middle frontal cortex (rMFC), ([Fig. 1](#f0005){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}). According to Eq. [(2)](#fo0010){ref-type="disp-formula"}, we obtained *RA*~BD-MDD~ = − 3.5%; that is, the CT of the BD group was 3.5% thinner than that of the MDD group in the left rMFC ([Table 2](#t0010){ref-type="table"}).Table 2Clusters with significant differences in cortical thickness across the three groups after correction for multiple comparisons.Cortical clusters showing significant differences in cortical thickness between the unmedicated adult patients with major depressive disorder (MDD) and the healthy controls (HC) as well as between the patients with bipolar depression (BD) and the HC. The cluster-based *p*-value corresponds to the peak vertex that showed the greatest statistical difference within a cluster. Abbreviations: L (R), left (right) hemisphere; rMFC, rostral middle frontal cortex; FPO, frontal pole; SFC, superior frontal cortex; ITC, inferior temporal cortex; FG, fusiform gyrus; PTRI, pars triangularis; LOC, lateral occipital cortex; IPC, inferior parietal cortex; lOFC, lateral orbitofrontal cortex; mOFC, medial orbitofrontal cortex. The Cohen *d* indicates the magnitude of the effect size.Table 2LocationPeak Talairach Coordinates*p*-ValueCohen *d* (statistical power)Cluster size (mm^2^)*CT*~MDD~ (mm)*CT*~BD~ (mm)*CT*~HC~ (mm)*RA*~MDD-HC~*RA*~BD-HC~*RA*~BD-MDD~BD \< MDDC1rMFC.L, FPO.L, SFC.L(− 23.1, 52.2, 7.0)5.00E − 040.62 (0.72)1353.02.4942.3982.4840.38%− 3.48%− 3.84%MDD \< HCC2ITC.L, FG.L(− 50.6, − 53.3, − 9.7)1.05E − 020.61 (0.68)934.42.3622.3102.468− 4.27%− 6.40%− 2.23%BD \< HCC3FPO.L, PTRI.L, rMFC.L, SFC.L(− 8.7, 62.5, − 6.6)1.00E − 040.99 (0.97)1846.82.4392.3262.4360.10%− 4.54%− 4.64%C4SFC.L(− 6.8, 32.7, 46.6)1.07E − 020.64 (0.70)928.93.0903.0123.159− 2.19%− 4.67%− 2.54%C5ITC.L, FG.L, LOC.L(− 50.5, − 53.7, − 9.2)3.70E − 030.62 (0.72)1077.42.4272.3792.521− 3.75%− 5.65%− 1.98%C6LOC.R, IPC.L(39.2, − 81.0, 5.6)2.42E − 020.62 (0.72)859.952.2572.1672.291− 1.48%− 5.41%− 3.99%C7PTRI.R, rMFC.R(47.7, 27.6, 0.6)1.00E − 030.62 (0.72)1228.52.3232.2382.331− 0.32%− 3.98%− 3.67%C8lOFC.R, mOFC.R(24.1, 24.9, − 12.7)2.46E − 020.62 (0.72)857.72.4322.3952.495− 2.53%− 4.02%− 1.53%MDD vs. HC: Compared to the controls, there is only one cluster that was significantly thinner in the MDD group (referred to as C2), which is located in the left inferior temporal cortex (ITC) ([Fig. 1](#f0005){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}). We obtained its *RA*~MDD-HC~ = − 4.3% according to Eq. [(3)](#fo0015){ref-type="disp-formula"}, indicating a thinner CT in the left ITC for the MDD group compared to the controls ([Table 2](#t0010){ref-type="table"}).BD vs. HC: We detected a significantly thinner CT in the BD group compared to the control group in six clusters (referred as C3, C4, C5, C6, C7, and C8, respectively), which are located in the left frontal pole (FPO), left superior frontal cortex (SFC), left ITC, right lateral occipital cortex (LOC), right pars triangularis (PTRI), and right lateral orbitofrontal cortex (lOFC) ([Fig. 1](#f0005){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}). According to Eq. [(4)](#fo0020){ref-type="disp-formula"}, we estimated the relative alteration in the CT in these six clusters and found that they were in the range of *RA*~BD~ = − 3.9% to − 5.7%, in the BD group compared to the control group ([Table 2](#t0010){ref-type="table"}).Fig. 1Vertex-based analysis of cortical thickness in the three groups, the unmedicated adult patients with major depressive disorder (MDD) and bipolar depression (BD) as well as the healthy controls (HC). Clusters were obtained from an independent samples *t*-test to show statistically significant between-group differences in cortical thickness (*p* \< 0.05). Clusters color-coded in blue indicate significantly decreased cortical thickness in the BD group compared to either the MDD or HC or in the MDD group compared to the HC. Clusters are overlaid on average inflated images with sulci displayed as dark relative to gyri. Abbreviations: L (R), left (right) hemisphere; rMFC, rostral middle frontal cortex; ITC, inferior temporal cortex; LOC, lateral occipital cortex; lOFC, lateral orbitofrontal cortex; FPO, frontal pole; SFC, superior frontal cortex; PTRI, pars triangularis.Fig. 1

3.3. Cluster-based Analysis {#s0080}
---------------------------

### 3.3.1. Rank of CT in the Clusters {#s0085}

[Fig. 2](#f0010){ref-type="fig"} shows an overview of the results of the rank analysis. For the eight clusters listed in [Table 2](#t0010){ref-type="table"}, six of them (C2, C4, C5, C6, C7, and C8) had the rank of *CT*~BD~ \< *CT*~MDD~ \< *CT*~HC~; that is, in these six clusters, the BD patients had the lowest CT, the controls had the highest CT, and the MDD patients were in between. For the other two clusters, C1 and C3, we obtained the rank of *CT*~BD~ \< *CT*~HC~ \< *CT*~MDD~; that is, the BD group showed the lowest CT, the MDD patients had the highest CT, and the controls were in between in the clusters of C1 and C3.Fig. 2Rank of the average cortical thickness in cluster-based analyses. On six clusters, which are located in the left inferior temporal (C2, C5), left superior frontal (C4), right lateral occipital (C6), right pars triangularis (C7), and right lateral orbitofrontal (C8), the patients with bipolar depression (BD) had the lowest while the healthy controls (HC) had the highest average cortical thickness. On the other two clusters, the left rostral middle frontal (C1) and the left frontal pole (C3), the BD patients showed the lowest while the MDD patients had the highest average cortical thickness. Bars and error bars correspond to the average cortical thickness and the standard deviation for a given subject group of MDD (orange), or BD (yellow), or HC (green).Fig. 2

### 3.3.2. Relative Alterations {#s0090}

[Fig. 3](#f0015){ref-type="fig"} shows the relative alterations in the CT in the eight clusters listed in [Table 2](#t0010){ref-type="table"}. Of these, six clusters (C2, C4, C5, C6, C7, and C8) showed a thinner CT in the two types of disorder patients compared to the controls. In addition, we found \|* RA*~BD-HC~ \| \> \|* RA*~MDD-HC~ \| in these six clusters; that is, the BD patients had a more severe reduction in the CT than the MDD patients. Compared to the control group, the MDD patients showed a relatively thinner CT (*RA*~MDD-HC~ \< 0, ranging from − 0.3% to − 4.3%) in six clusters (C2, C4, C5, C6, C7 and C8), but a relatively thicker CT (*RA*~MDD-HC~ \> 0, ranging from 0.1% to 0.2%) in the other two clusters (C1 and C3). Compared to the control group, the BD patients showed a relatively thinner CT in all eight clusters (*RA*~BD-HC~ \< 0, ranging from − 3.2% to − 6.1%).Fig. 3Relative alteration in average cortical thickness derived from the cluster-based analysis. (a) Patients with major depressive disorder (MDD) compared to healthy controls (HC). (b) Patients with bipolar depression (BD) compared to HC. The clusters coded in warm (cold) color indicate significantly increased (decreased) cortical thickness in the two types of patients compared to the HC.Fig. 3

### 3.3.3. Relationship Between CT and Clinical Variables {#s0095}

[Fig. 4](#f0020){ref-type="fig"} shows the correlations between the CT and clinical variables in the BD group. The statistical analysis revealed a significantly positive correlation between the mean CT in the left FPO (C3) and the onset age (*r* = 0.387, *p* = 0.034) but a negative correlation between the mean CT in the right PTRI (C7) and the number of episodes (*r* = − 0.418, *p* = 0.022). However, for the MDD group, no significant correlation was found between the CT and any of the clinical variables. Unfortunately, the significant result can\'t survive after the FDR correction.Fig. 4Relationship between the cortical thickness and clinical variables. The scatter plot shows that the mean cortical thickness values for the clusters in the left frontal pole (C3) and the left pars triangularis (C7) changed with the onset age or number of depressive episodes. The correlation analysis was only performed for the patients with bipolar depression (BD). The symbol '+' in yellow color represents a subject in the BD group. LH (RH), left (right) hemisphere.Fig. 4

4. Discussion {#s0100}
=============

Using an SBM analysis, we compared the CT between the currently unmedicated depressed adult MDD patients, BD-II patients, and the healthy controls. We found that both the MDD and BD groups shared common CT abnormalities and the BD group had its specific CT abnormalities. Specifically, both the BD and MDD groups showed a thinner CT in the left ITC compared to the controls. Additionally, the BD group had a significantly thinner CT in the left rMFC compared to the MDD group. Finally, the BD group showed additional alterations primarily in the frontal lobe compared to the control group and had a tendency toward a thinner CT in most areas of the whole brain compared to either the MDD group or the control group.

4.1. Common Alteration in Cortical Thickness in MDD and BD {#s0105}
----------------------------------------------------------

In this study, both the MDD and BD groups showed a significantly thinner CT in the left ITC compared to the controls ([Fig. 1](#f0005){ref-type="fig"}). This result is consistent with several previous studies ([@bb0325], [@bb0105]). For example, [@bb0105] analyzed the CT difference between BD-II patients and healthy controls and found that the BD-II group showed a significantly thinner CT in the left temporal region involving the superior, middle, and inferior temporal cortex. [@bb0325] revealed that patients with treatment-resistant MDD had a thinner CT in the ITC compared to healthy controls. Meanwhile, several studies also reported GM tissue losses in the ITC in patients with MDD and BD ([@bb0160]).

Previous study ([@bb0205]) indicated that the ITC belongs to the ventral stream of visual processing, and is associated with the representation of complex object features, such as face perception ([@bb0185]) and the recognition of numbers ([@bb0080]). And several other studies also indicated that it may be involved in o emotional processing ([@bb0330], [@bb0230]). [@bb0235] reported decreased activation in the ITC when MDD patients responded to sadness stimuli. Similarly, [@bb0155] found that the MDD patients had significantly reduced responses to the happy facial expressions in the right ITC compared to the healthy controls. In addition, [@bb0230] found both memory-driven sadness and anxiety caused a decrease in the cerebral blood flow in the bilateral posterior ITC in BD patients. Taken together, our finding provides an evidence for the ITC may contribute to these two disorders.

4.2. Specific Alteration in Cortical Thickness Between MDD and BD {#s0110}
-----------------------------------------------------------------

Compared to the MDD patients and controls, the BD patients showed a significantly thinner CT in the left rMFC ([Fig. 1](#f0005){ref-type="fig"}), which is the gyral-based representative of the dorsolateral prefrontal cortex (DLPFC, a functionally defined area) ([@bb0090]). This result is consistent with a previous study, in which [@bb0215] found less CT in the right DLPFC in BD patients compared to either MDD patients or healthy controls. Savitz and Drevets reviewed past MRI and metabolic PET studies in MDD and BD patients and suggested that the BD patients tended to display evidence of DLPFC GM volume loss ([@bb0335]). Such changes are consistent with aberrant DLPFC gene expression in patients with BD ([@bb0340], [@bb0345]). Using a stereological 3D cell counting method, [@bb0350] demonstrated that the DLPFC from BD patients is characterized by significant reductions in glial density and changes in the shape of the glial nuclei and that their alterations are accompanied by reductions in neuronal density. This histopathological evidence from neurons and glial cells may be related to the reduction of the CT in BD patients.

The DLPFC is widely believed involving in the executive function ([@bb0355]), such as working memory ([@bb0015], [@bb0060]), planning ([@bb0360]), and attentional control ([@bb0195]). Actually, a previous study indicated that the deficit in executive function in BD is an important prognostic factor ([@bb0180]). As a part of the cortico-thalamic-insular circuit, the DLPFC is also involved in the pathophysiology of mood disorders. In this neural circuitry model, a deficit in DLPFC would result in decreased cortical regulation of emotional processing. For example, [@bb0150] and [@bb0365] revealed that re-evaluation of negative stimuli is positively correlated with activity in the DLPFC in healthy volunteers. And several task-fMRI studies also found increased activity in the DLPFC during suppression of negative emotions ([@bb0225], [@bb0370]). [@bb0375] investigated emotion regulation in patients with MDD and BD using task-fMRI and found that the BD patients had more seriously impaired emotion regulation. Additionally, they showed increased DLPFC activity in the BD patients compared to the MDD patients and healthy controls in an emotion regulation task, particularly in the sad emotion regulation task. Our findings indicate that the structural differences in the DLPFC in BD and MDD may be related to different clinical symptoms in these two disorders.

4.3. Pronounced Thinner Cortical Thickness in BD {#s0115}
------------------------------------------------

In this study, the thinner CT in the BD patients versus the controls were observed in widespread areas, mainly located in the frontal lobe but also in the LOC ([Fig. 1](#f0005){ref-type="fig"}). Our results indicate that these findings are a BD-specific phenomenon, as we did not find them in the MDD patients. We found less CT in the dorsal PFC, including the SFC, PTRI, and rMFC, in the BD patients. Less CT of the left SFC was also observed in the BD patients compared to the controls in our study. The same finding of GM loss in the SFC was reported not only in previous SBM analyses ([@bb0265], [@bb0175]) but also in VBM analyses ([@bb0240]) in BD patients. In addition, a resting state fMRI study found significantly decreased functional connectivity in DLPFC networks in BD patients versus control subjects ([@bb0095]), and a ROI-based DTI study reported reduced fractional anisotropy in the superior frontal WM in BD patients ([@bb0020]). Moreover, we found that the BD patients showed a thinner CT in the left PTRI compared to the control group. This result is also consistent with several previous VBM studies. For example, [@bb0380] reported reduced GM density in the left PTRI in BD patients, and [@bb0265] found two clusters with abnormal GM density in the PTRI which were correlated with HAMD scores in BD patients. Our finding provides evidence that the CT of the PTRI is correlated inversely with the number of depressive episodes in BD patients. This means the more number of episodes may be associated with more pronounced alteration in cortical morphology in the PTRI. This finding may suggest that the CT defect in the PTRI in BD is an indicator of the number of episodes in recurrent BD.

Cortical thinning in the BD patients was not only observed in the dorsal PFC but also in the ventral prefrontal cortex (VPFC) which includes the FPO and lOFC. In a previous postmortem study, [@bb0055] found evidence of reduced glial cell density and neuronal size in the caudal OFC of BD patients. This finding indicated that tissue loss in the OFC seems to be a characteristic of BD patients. Several DTI studies also found disrupted structural integrity of WM tracts in the OFC in adult ([@bb0030], [@bb0190]) and pediatric ([@bb0135]) BD patients. We also observed that the BD patients had a thinner CT in the left FPO and that the mean CT in this region was significantly positively correlated with the onset age in the BD patients ([Fig. 4](#f0020){ref-type="fig"}). This means that early disorder-onset may be associated with more pronounced changes in cortical morphology in the FPO relative to late disorder-onset. Generally, the VPFC is associated with emotion regulation and evaluation during emotion processing ([@bb0385], [@bb0390]). Several studies have documented that BD patients manifested abnormal functional connectivity between the VPFC and other task-related brain areas during emotional-processing and regulation tasks ([@bb0395], [@bb0400], [@bb0085]). Thus, we infer that the thinning of the VPFC may be related to abnormal emotion processing in BD patients.

In this study, more pronounced thinner CT was found in the BD patients than in the MDD patients. Specifically, we found that the BD patients had the lowest CT in all the clusters listed in [Table 2](#t0010){ref-type="table"} that showed differences between any two groups ([Fig. 2](#f0010){ref-type="fig"}) and that the BD patients showed a higher reduction rate in CT than the MDD patients ([Fig. 3](#f0015){ref-type="fig"}). Alterations in CT in severe mental disorders, such as schizophrenia and BD, have been suggested as being due to a reduced number of synaptic contacts in affected areas ([@bb0170]) or to neuronal apoptosis ([@bb0145]). Our findings are in accord with several previous studies, which revealed that BD patients had more widespread WM abnormalities, GM volume reductions, and different aberrant functional connectivity in the neural circuits responsible for emotion regulation, attentional control, and reward-processing compared to MDD patients ([@bb0140], [@bb0380]). This is not surprising, given that BD is considered to be a more chronic illness and is associated with an earlier age of onset and more episodes of major depression compared with MDD ([@bb0405]). In addition, we found lower cortical thickness in the left hemisphere in the BD patients than the MDD patients and the controls. Actually, the issue of lateralized hemispheric imbalance in BD has not been systematically explored and several hypothesis-driven morphometric studies in BD have reported right-lateralized findings in BD ([@bb0410], [@bb0005]). Surely, the significance of lateralized findings is needed to be well studied in the future.

We also noticed some discrepancy between this study and previous studies. Although several studies reported aberrant GM in the PFC and anterior cingulate cortex (ACC) in MDD patients ([@bb0325], [@bb0045]), we did not find decreased CT in these regions in the MDD patients. This discrepancy may have resulted from a number of factors. A possible factor is the relative small sample size of our study. In addition, the patients in our sample were unmedicated at the time of their scan; most of them were medication-naïve, which could partly account for some of our findings that are discrepant from previously published works which included medicated patients. In fact, the effect of medication on GM has been well documented in MDD and BD patients ([@bb0220], [@bb0035]). Furthermore, most studies compared combined samples of BD-I and BD-II patients with MDD patients and controls ([@bb0215], [@bb0140]). [@bb0265] reported brain volumetric, thickness, and WM integrity differences between BD-I and BD-II and suggested that abnormal regional brain volume may underlie BD-I but not BD-II. This issue needs to be considered in a future study.

5. Limitations {#s0120}
==============

There are several limitations to be addressed in this study. First, the samples of patients may not fully represent the MDD and BD populations. A previous study indicated that, due to the potential instability of the diagnosis, based on an epidemiological study, approximately 1--5% of MDD subjects will develop BD more than one year after their initial identification ([@bb0415]). Second, multiple recurrent episodes of conditions in the BD and MDD patients may have impacted the observed morphometric abnormalities. Third, the MDD group showed not only significantly lower in the years of education than the controls, but also significantly higher YMRS score than the BD patients. These may potentially have biased the observed morphometric abnormalities. Therefore, we assessed if the cortical thickness difference was associated with YMRS score or years of education, and found that cortical thickness in these clusters had no significant correlations with years of education or YMRS score. In addition, changes to cortical thickness by some confounders cannot be considered in this study, such as IQ, medication history and rapid cycling in BD patients. Furthermore, the significant results of correlation didn\'t survive after the FDR correction. A future replication study that examines the CT using FreeSurfer by separating first-episode and recurrent episodes of BD or MDD patients in a larger matched sample would be beneficial for elucidating the underlying neurobiological differences between BD and MDD patients. Last but not least, because we carried out a cross-sectional study, we cannot infer whether the abnormal CT in the patients was caused by the brain disorders or whether the patients had innate abnormal brain structures (e.g., neural disposition, genetic origins). A longitudinal study is needed to find evidence for disorder-induced CT changes.

6. Conclusion {#s0125}
=============

In summary, we estimated the cortical thickness in unmedicated adult patients with MDD or BD and controls by using a surface-based morphometric analysis and revealed the alteration patterns in the MDD and BD patients that were either in common between the disease groups or specific to one of the groups. Relative to the healthy controls, the two patient groups showed reduced cortical thickness in the left ITC in common. However, compared with the MDD patients, the BD patients displayed widespread reduction in cortical thickness in brain regions primarily located in the frontal lobe. Our results also showed that the BD patients had the lowest cortical thickness in widespread areas of the whole brain relative to the other two groups. These findings seem to imply that BD and MDD have different underlying pathophysiological mechanisms and may be useful for classifying individual patients with either MDD or BD.
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[^3]: Difference in gender was tested using a *χ*^2^-test. Differences in age and years of education across the three groups were tested using a one-way ANOVA. An independent samples *t*-test was used to determine group differences in the age of onset, illness duration, number of depressive episodes, HDRS scores, and YMRS scores, which were only available for the two patient groups (MDD and BD).
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[^7]: ANOVA significant (*p* \< 0.01).
